CorMedix Inc. (CRMD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with CRMD?
Powered by Yahoo ScoutCorMedix (CRMD) recently received an upgrade to a Buy ratingdue to rising earnings estimates. The company reported a significant Q2 revenue of $101.9 million, driven by strong sales from its DefenCath product, and analysts project a potential 66% upsidebased on current price targets.
- Previous Close
8.47 - Open
8.45 - Bid 5.35 x 200
- Ask 9.71 x 200
- Day's Range
8.31 - 8.60 - 52 Week Range
6.13 - 13.83 - Volume
792,812 - Avg. Volume
1,288,828 - Market Cap (intraday)
657.071M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
3.88 - EPS (TTM)
2.17 - Earnings Date Nov 16, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.40
Recent News
View MorePerformance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
40.49%
-
Return on Assets (ttm)
24.56%
-
Return on Equity (ttm)
54.93%
-
Revenue (ttm)
462.25M
-
Net Income Avi to Common (ttm)
186.02M
-
Diluted EPS (ttm)
2.17
Balance Sheet and Cash Flow
-
Total Cash (mrq)
256.69M
-
Total Debt/Equity (mrq)
32.00%
-
Levered Free Cash Flow (ttm)
178.14M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
